First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
Status:
Recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
The PhAST Trial is an adaptive first-in-human clinical trial of the
acetylglucosaminyltransferase V inhibitor PhOx430 in patients with advanced solid tumours
conceived and designed with the contribution of the Gianni Bonadonna Foundation, a non-profit
academic research institution aimed at promoting therapeutic innovation in oncology.. The
trial includes two parts, a dose escalation phase which will enroll patients with
non-selected tumour types, followed by a cohort expansion phase in selected tumour types.